Skip to main navigation Skip to search Skip to main content

Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies

  • Ahern, Elizabeth (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusFinished
Effective start/end date20/07/21 → 19/07/26

Keywords

  • phase 1 and 2 study
  • treatment safety
  • treatment efficacy
  • solid tumour

Clinical Trial Phase

  • Phase I
  • Phase II